The Histone Lysine N Methyltransferase EZH1 pipeline drugs market research report outlays comprehensive information on the Histone Lysine N Methyltransferase EZH1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Histone Lysine N Methyltransferase EZH1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Infectious Disease which include the indications Diffuse Large B-Cell Lymphoma, Solid Tumor, and Respiratory Syncytial Virus (RSV) Infections. It also reviews key players involved in Histone Lysine N Methyltransferase EZH1 targeted therapeutics development with respective active and dormant or discontinued products.
The Histone Lysine N Methyltransferase EZH1 pipeline targets constitutes close to nine molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 4, 1, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Histone Lysine N Methyltransferase EZH1 overview
Histone Lysine N Methyltransferase is an enzyme that in humans is encoded by a gene EZH1. This is also known as Enhancer of Zeste Homolog 1 that belongs to the Polycomb group protein family. It’s involved in epigenetic regulation, which means it helps control gene expression without altering the DNA sequence itself. The main role of EZH1 is to add methyl groups to histone proteins. Histones are proteins that DNA wraps around, forming a structure called chromatin. By adding methyl groups to histones, EZH1 contributes to the formation of a repressive chromatin state. This repressive state typically results in the inhibition of gene transcription, meaning that the associated genes are less likely to be expressed. EZH1 helps to regulate which genes are turned on or off within a cell, playing a crucial role in various cellular processes, including development, differentiation, and the maintenance of cell identity. Dysregulation of EZH1 activity has been implicated in various diseases, including cancer, where improper gene expression can contribute to uncontrolled cell growth.
For a complete picture of Histone Lysine N Methyltransferase EZH1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
